Want to join the conversation?
In Oct. 2015, $LLY acquired the worldwide rights to Canadian firm Locemia Solutions' intranasal glucagon, a glucagon nasal powder being investigated for the treatment for severe hypoglycemia. Upon entry into the agreement, $LLY paid approx. $150MM, which will be accounted for in the fourth quarter of 2015.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.